Grifols, S.a. Share Price (NASDAQ: GRFS)

$9.8

▲

-0.04

(-0.41%)

Last updated on August 28, 2025 at 1:29 am IST

$₹

Check the interactive Grifols, S.a. Stock chart to analyse performance

Grifols, S.a. stock performance

as on August 28, 2025 at 1:29 am IST

Today's Low:$9.80
Today's High:$9.91
$9.80
0.0%
Downside
Day's Volatility :1.11%
Upside
1.11%
52 Weeks Low:$6.19
52 Weeks High:$11.14
$9.80
36.84%
Downside
52 Weeks Volatility :44.43%
Upside
12.03%

Grifols, S.a. Stock Returns

Period	Grifols, S.a.	Sector (Health Care)	Index (Russel 2000)
3 Months	17.64%	3.7%	0.0%
6 Months	18.78%	-6.9%	0.0%
1 Year	9.28%	-11.9%	0.0%
3 Years	27.56%	7.7%	-6.9%

Grifols, S.a. Key Stats

Check Grifols, S.a. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$9.84
Open	$9.9
Today's High	$9.91
Today's Low	$9.8
Market Capitalization	$8.4B
Today's Volume	$412.5K
52 Week High	$11.14
52 Week Low	$6.19
Revenue TTM	$7.4B
EBITDA	$1.7B
Earnings Per Share (EPS)	$0.51
PE Ratio	19.25
Dividend Yield	1.73%
Profit Margin	4.0%
Quarterly Earnings Growth YOY	7.5%
Return On Equity TTM	4.99%

Stock Returns calculator for Grifols, S.a. Stock including INR - Dollar returns

The Grifols, S.a. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Grifols, S.a. investment value today

Current value as on today

₹1,13,574

Returns

₹13,574

(+13.57%)

Returns from Grifols, S.a. Stock

₹8,889 (+8.89%)

Dollar Returns*

₹4,685 (+4.68%)

Indian investors sentiment towards Grifols, S.a. Stock

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Search interest for Grifols, S.a. Stock from India on INDmoney has increased by 9% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Grifols, S.a.

Name
Holdings %
Name
Holdings %
Brandes Investment Partners & Co
4.12%
Capital World Investors
3.18%
Permian Investment Partners
2.66%
Black Creek Investment Management Inc
1.85%
Millennium Management LLC
1.26%
Armistice Capital, LLC
1.07%

Analyst Recommendation on Grifols, S.a. Stock

Rating

Trend

Buy

63%Buy

22%Hold

13%Sell

Based on 22 Wall street analysts offering stock ratings for Grifols, S.a.(by analysts ranked 0 to 5 stars)

Grifols, S.a. Share Price Target

What analysts predicted

Upside of 24.34%

Target:

$12.19

Current:

$9.80

Grifols, S.a. share price target is $12.19, a slight Upside of 24.34% compared to current price of $9.80 as per analysts' prediction.

Grifols, S.a. Stock Insights

Price Movement
In the last 7 days, GRFS stock has moved down by -3.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.78B → 1.89B (in $), with an average increase of 5.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 59.72M → 117.06M (in $), with an average increase of 49.0% per quarter

Grifols, S.a. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$5.1B	↑ 13.64%
Net Income	$625.1M	↑ 4.78%
Net Profit Margin	12.26%	↓ 1.04%

	FY20	Y/Y Change
Revenue	$5.3B	↑ 4.73%
Net Income	$618.5M	↓ 1.06%
Net Profit Margin	11.58%	↓ 0.68%

	FY21	Y/Y Change
Revenue	$5.6B	↓ 7.62%
Net Income	$299.9M	↓ 57.1%
Net Profit Margin	5.38%	↓ 6.2%

	FY22	Y/Y Change
Revenue	$6.4B	↑ 22.92%
Net Income	$220.4M	↓ 21.5%
Net Profit Margin	3.43%	↓ 1.95%

	FY23	Y/Y Change
Revenue	$7.2B	↑ 8.71%
Net Income	$64.7M	↓ 71.52%
Net Profit Margin	0.9%	↓ 2.53%

	FY24	Y/Y Change
Revenue	$7.5B	↑ 9.41%
Net Income	$164.2M	↑ 164.55%
Net Profit Margin	2.18%	↑ 1.28%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$1.6B	↓ 8.13%
Net Income	$21.4M	↓ 61.75%
Net Profit Margin	1.32%	↓ 1.84%

	Q2 FY24	Q/Q Change
Revenue	$2.0B	↑ 11.82%
Net Income	$16.0M	↓ 30.71%
Net Profit Margin	0.82%	↓ 0.5%

	Q3 FY24	Q/Q Change
Revenue	$2.0B	↓ 1.37%
Net Income	$57.4M	↑ 248.3%
Net Profit Margin	2.88%	↑ 2.06%

	Q4 FY24	Q/Q Change
Revenue	$2.1B	↑ 10.2%
Net Income	$72.2M	↑ 33.42%
Net Profit Margin	3.49%	↑ 0.61%

	Q1 FY25	Q/Q Change
Revenue	$1.8B	↓ 9.62%
Net Income	$59.7M	↓ 13.4%
Net Profit Margin	3.34%	↓ 0.15%

	Q2 FY25	Q/Q Change
Revenue	$1.9B	↑ 5.9%
Net Income	$117.1M	↑ 96.0%
Net Profit Margin	6.19%	↑ 2.85%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$2.3B	↑ 14.23%

	FY20	Y/Y Change
Profit	$2.3B	↓ 3.68%

	FY21	Y/Y Change
Profit	$2.2B	↓ 12.97%

	FY22	Y/Y Change
Profit	$2.4B	↑ 13.7%

	FY23	Y/Y Change
Profit	$2.5B	↑ 4.09%

	FY24	Y/Y Change
Profit	$2.9B	↑ 20.31%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$648.4M	↓ 6.0%

	Q2 FY24	Q/Q Change
Profit	$668.0M	↓ 4.26%

	Q3 FY24	Q/Q Change
Profit	$807.0M	↑ 17.07%

	Q4 FY24	Q/Q Change
Profit	$801.9M	↑ 5.47%

	Q1 FY25	Q/Q Change
Profit	$704.6M	↓ 8.07%

	Q2 FY25	Q/Q Change
Profit	$743.8M	↑ 5.56%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$568.9M	↓ 22.85%
Investing Cash Flow	$-548.8M	↓ 29.81%
Financing Cash Flow	$-332.4M	↓ 317.93%

	FY20	Y/Y Change
Operating Cash Flow	$1.1B	↑ 95.16%
Investing Cash Flow	$-858.1M	↑ 56.37%
Financing Cash Flow	$-354.4M	↑ 6.63%

	FY21	Y/Y Change
Operating Cash Flow	$674.9M	↓ 46.23%
Investing Cash Flow	$-33.2M	↓ 96.57%
Financing Cash Flow	$1.7B	↓ 515.61%

	FY22	Y/Y Change
Operating Cash Flow	$-11.5M	↓ 101.82%
Investing Cash Flow	$-2.1B	↑ 6632.29%
Financing Cash Flow	$-183.6M	↓ 111.78%

	FY23	Y/Y Change
Operating Cash Flow	$238.6M	↓ 2112.42%
Investing Cash Flow	$-433.8M	↓ 79.91%
Financing Cash Flow	$203.0M	↓ 207.23%

	FY24	Y/Y Change
Operating Cash Flow	$943.9M	↑ 312.53%
Investing Cash Flow	$927.7M	↓ 322.98%
Financing Cash Flow	$-1.4B	↓ 830.31%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Operating Cash Flow	$170.6M	↑ 0.48%
Investing Cash Flow	$-154.8M	↑ 15.46%
Financing Cash Flow	$50.7M	↓ 158.55%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-179.3M	↓ 205.46%
Investing Cash Flow	$-95.6M	↓ 38.01%
Financing Cash Flow	$179.8M	↑ 256.0%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$272.1M	↓ 253.32%
Investing Cash Flow	$1.5B	↓ 1634.17%
Financing Cash Flow	$64.0M	↓ 64.08%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$332.7M	↑ 18.49%
Investing Cash Flow	$-218.1M	↓ 114.56%
Financing Cash Flow	$-1.7B	↓ 2718.52%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$538.4M	↑ 71.76%
Investing Cash Flow	$-186.6M	↓ 9.21%
Financing Cash Flow	$-28.4M	↓ 98.25%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$146.5M	↓ 73.68%
Investing Cash Flow	$-213.4M	↑ 10.68%
Financing Cash Flow	$-144.5M	↑ 392.08%

Grifols, S.a. Technicals Summary

Sell

Neutral

Buy

Grifols, S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Grifols, S.a. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Grifols, S.a.	-6.33%	18.78%	9.28%	27.56%	-38.65%
Eli Lilly And Company	-8.95%	-18.71%	-22.47%	137.23%	395.83%
Johnson & Johnson	5.0%	7.81%	7.68%	8.29%	15.06%
Merck & Co. Inc.	2.94%	-6.09%	-27.55%	-2.89%	-0.25%
Novo Nordisk A/s	2.57%	-37.99%	-58.86%	2.99%	67.55%
Abbvie Inc	8.98%	1.65%	6.65%	53.56%	117.6%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Grifols, S.a.	19.25	19.25	0.23	0.97	0.05	0.04	0.02	7.6
Eli Lilly And Company	48.11	48.11	1.07	22.87	0.86	0.17	0.01	20.38
Johnson & Johnson	19.1	19.1	1.09	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	13.14	13.14	0.86	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	14.48	14.48	1.67	24.84	0.79	0.22	0.03	37.82
Abbvie Inc	99.81	99.81	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Grifols, S.a.	Buy	$8.4B	-38.65%	19.25	4.0%
Eli Lilly And Company	Buy	$659.8B	395.83%	48.11	25.91%
Johnson & Johnson	Buy	$429.7B	15.06%	19.1	25.0%
Merck & Co. Inc.	Buy	$213.1B	-0.25%	13.14	25.79%
Novo Nordisk A/s	Buy	$244.2B	67.55%	14.48	35.61%
Abbvie Inc	Buy	$372.0B	117.6%	99.81	6.45%

Grifols, S.a. Dividend announcements

Grifols, S.a. Dividends September, 2025
In the quarter ending September,2025. Grifols, S.a. has declared dividend of $0.17

About Grifols, S.a.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Organization	Grifols, S.a.
Employees	23833
CEO	Mr. Jose Ignacio Abia Buenache
Industry	Health Technology

Key Management of Grifols, S.a.

Name	Title
Mr. Víctor Grifols Deu	Executive Director
Mr. Jose Ignacio Abia Buenache	CEO & Director
Mr. Rahul Srinivasan	Chief Financial Officer
Mr. Lluis Pons Gomez	Senior Vice President of Strategy & COO Office
Daniel Segarra	Head of Investor Relations & Sustainability and Vice President
Mr. David Ian Bell	Chief Corporate Affairs & Legal Officer
Mr. Enrique de la Torre	Chief Compliance Officer
Ms. Montse Ribas	Chief Communications and Reputation Officer
Mr. Camille Alpi	Chief Human Resources & Talent Officer
Mr. Vicente Blanquer Torre	Chief Quality Officer

Important FAQs about investing in GRFS Stock from India :

What is Grifols, S.a. share price today?

Grifols, S.a. share price today is $9.80 as on August 28, 2025 at 1:29 am IST at the close of the market. Grifols, S.a. share today touched a day high of $9.91 and a low of $9.80.

What is the 52 week high and 52 week low for Grifols, S.a. share?

Grifols, S.a. share touched a 52 week high of $11.14 and a 52 week low of $6.19. Grifols, S.a. stock price today i.e. August 28, 2025 at 1:29 am IST is closed at $9.80, lower by 12.03% versus the 52 week high.

How to invest in Grifols, S.a. Stock (GRFS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Grifols, S.a. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Grifols, S.a. Shares that will get you 0.1531 shares as per Grifols, S.a. share price of $9.80 per share as on August 28, 2025 at 1:29 am IST.

What is the minimum amount required to buy Grifols, S.a. Stock (GRFS) from India?

Indian investors can start investing in Grifols, S.a. (GRFS) shares with as little as ₹87.86 or $1 (as of August 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.60 in Grifols, S.a. stock (as per the Rupee-Dollar exchange rate as on August 28, 2025). Based on Grifols, S.a. share’s latest price of $9.80 as on August 28, 2025 at 1:29 am IST, you will get 1.0204 shares of Grifols, S.a.. Learn more about fractional shares .

What are the returns that Grifols, S.a. has given to Indian investors in the last 5 years?

Grifols, S.a. stock has given -38.65% share price returns and 18.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?